Li Xiaoguang, Hong Yuan, Wang Qi, Liu Shunai, Wei Hongshan, Cheng Jun
Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing, 100015, China.
Department of Infectious Diseases, The Second Affiliated Hospital of Harbin Medical University, No. 246 Xuefu Road, Harbin, 150086, Heilongjiang, China.
Hepatol Int. 2013 Mar;7(1):127-33. doi: 10.1007/s12072-012-9377-0. Epub 2012 May 27.
To assess the functions of mismatched short hairpin RNAs (shRNAs) that inhibit replication and the expression of hepatitis B virus (HBV), two shRNAs possessing a 2- or 3-base mismatch that targeted HBV were studied.
shRNAs and pHY106-HBV were cotransfected into HepG2 cells. The culture supernatants were collected and used in hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) assays. The levels of HBsAg and HBcAg mRNA were detected by reverse-transcriptase PCR (RT-PCR). HBV DNA replication intermediates were extracted for Southern blot hybridization.
The results demonstrate that mismatched shRNA-458 and shRNA-635 can significantly inhibit HBsAg and HBeAg protein expression, and the maximal inhibition ratio for both proteins was found at 72 h after cotransfection: 80 and 50 %, respectively. Similar inhibitory effects were found on HBsAg and HBcAg mRNA levels and HBV DNA replication intermediates at 72 h after cotransfection, and the inhibition ratio was found to be approximately 70 and 90 %, respectively.
Despite the 2- or 3-base mismatch between the shRNAs and the HBV target sequences, shRNA-458 and shRNA-635 exerted a significant inhibitory effect on HBsAg and HBeAg expression and HBV replication. This indicates that mismatched shRNAs could be a promising therapy for HBV.
评估抑制乙型肝炎病毒(HBV)复制和表达的错配短发夹RNA(shRNA)的功能,研究了两种与HBV靶点有2个或3个碱基错配的shRNA。
将shRNA与pHY106-HBV共转染到HepG2细胞中。收集培养上清液并用于乙型肝炎表面抗原(HBsAg)和乙型肝炎e抗原(HBeAg)检测。通过逆转录聚合酶链反应(RT-PCR)检测HBsAg和HBcAg mRNA水平。提取HBV DNA复制中间体用于Southern印迹杂交。
结果表明,错配的shRNA-458和shRNA-635可显著抑制HBsAg和HBeAg蛋白表达,共转染后72小时两种蛋白的最大抑制率分别为80%和50%。共转染后72小时,对HBsAg和HBcAg mRNA水平及HBV DNA复制中间体也有类似的抑制作用,抑制率分别约为70%和90%。
尽管shRNA与HBV靶序列之间存在2个或3个碱基错配,但shRNA-458和shRNA-635对HBsAg和HBeAg表达及HBV复制仍有显著抑制作用。这表明错配的shRNA可能是一种有前景的HBV治疗方法。